Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Rhea-AI Summary

Calidi Biotherapeutics (NYSE American: CLDI) is developing a next-generation platform for cancer treatment using engineered viruses to deliver genetic medicines directly to tumors. The company's innovative approach targets both primary and metastatic tumors, addressing a critical healthcare need as cancer diagnoses are projected to reach 35 million annually by 2050.

While initially focused on oncology, Calidi is also exploring applications in autoimmune disorders. This development comes as global cancer cases reach 20 million diagnoses and 10 million deaths annually, highlighting the urgent need for more effective treatment options.

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers,” please visit: https://nnw.fm/zBrXc.

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades (https://ibn.fm/dyQrw). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant.

Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi’s technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, visit the company’s website at www.calidibio.com .

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

FAQ

What is Calidi Biotherapeutics' (CLDI) approach to cancer treatment?

Calidi Biotherapeutics is developing a platform that uses engineered viruses to deliver genetic medicines directly to primary and metastatic tumors, aiming to improve cancer treatment effectiveness.

What is the market potential for Calidi Biotherapeutics' (CLDI) cancer treatment platform?

The market potential is significant, with global cancer diagnoses projected to reach 35 million annually by 2050, up from the current 20 million cases per year.

What other therapeutic areas is Calidi Biotherapeutics (CLDI) exploring beyond cancer?

Beyond oncology, Calidi Biotherapeutics is exploring applications of its platform technology in treating autoimmune disorders.

How many people are affected by cancer globally according to CLDI's release?

According to the release, approximately 20 million people are diagnosed with cancer annually, with nearly 10 million deaths worldwide.